[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603324":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":38,"locations":49,"responsibleParty":76,"collaborators":64,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":64,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":64,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":64,"overallStatus":67,"whyStopped":64,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Kafrelsheikh University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"sildn arm","ACTIVE_COMPARATOR","In this group, participants receive sildenafil 25 mg thrice a day. then amniotic fluid index is measured every week to measure its improvement. After delivery, APGAR will be measured. As well as, whether the fetus entered the NICU or not will be recorded.",[13],"Drug: Sildenafil 25 MG",{"label":15,"type":10,"description":16,"interventionNames":17},"L- argin arm","In this group, participants receive L- arginine 1000 mg thrice a day. then amniotic fluid index is measured every week to measure its improvement. After delivery, APGAR will be measured. As well as, whether the fetus entered the NICU or not will be recorded.",[18],"Drug: L-Arginine, 1000 Mg Oral Tablet",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Sildenafil 25 MG","Sildenafil is a vasodilator drug which improve blood supply to placenta.Therefore, it should improve idiopathic oligohydramnios.",[9],[26],"Viagra",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"L-Arginine, 1000 Mg Oral Tablet","Aminoacid with vasodilator property which improve blood supply to placenta.Therefore, it should improve idiopathic oligohydramnios.",[15],[32],"L- arginine",[34],{"name":35,"affiliation":36,"role":37},"Dalia S Zolfakar, PHD","daliasamir94@gmail.com","STUDY_DIRECTOR",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Ibtesam T Gadalla, MBBch","CONTACT","1025193157","0020","bassmagadalla@gmail.com",{"name":46,"role":41,"phone":47,"phoneExt":43,"email":48},"Mostafa F El-lakany, PHD","10116083210","Mfe_2014@yahoo.com",[50,65],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Kafrelsheikh University Hospital","ACTIVE_NOT_RECRUITING","Kafr ash Shaykh","Kafrelsheikh","33513","Egypt","EG",{"type":59,"coordinates":60},"Point",[61,62],30.93991,31.11174,{"lat":62,"lon":61},null,{"facility":66,"status":67,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"Kafrelsheokh university hospital","RECRUITING",{"type":59,"coordinates":69},[61,62],{"lat":62,"lon":61},[72],{"name":73,"role":41,"phone":74,"phoneExt":64,"email":75},"Ahmed A Ali, Professor","0020-1005688624","medical_research@kfs.edu.eg",{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":64,"oldOrganization":64},"PRINCIPAL_INVESTIGATOR","Ibtesam Teleb Mohamed Yousef Gadalla","principle investigator","100603324","phase-2-comparison-between-treatments-of-oligohydramnios-100603324",false,"NCT07135037","Comparison Between Treatments of Oligohydramnios","Efficacy of L- Arginine Versus Sildenafil in Management of Idiopathic Oligohydramnios","Inclusion Criteria:\n\n* Pregnant women with gestational age between 26-37 weeks\n* Pregnant women whose age is \\\u003C 35 years\n* Woman with other indication for elective caesarean section.\n* Women carrying a single fetus with no major anomalies.\n* Initial amniotic fluid index \\\u003C8cm determined by reliable pelivabdominal ultrasound.\n\nExclusion Criteria:\n\n* Women complaining of other obstetric disorder such as, PPROM, preeclampsia, or diabetes.\n* Women with chronic illness such as, chronic hypertension, autoimmune disease or kidney disease.\n* Women who received other treatments for oligohydramnios in current pregnancy.\n* Women who smoke.\n* Fetuses with major congenital anomaly.",true,"FEMALE","18 Years","35 Years",{"count":92,"type":93},40,"ESTIMATED","INTERVENTIONAL",[96],"PHASE2","Based on previous studies, Both sildenafil and L-arginine helped to improve idiopathic oligohydramnios.\n\nIn this study, Level of improvment of oligohydramnios will be compared. As well as, NICU admission to neonates of pregnancies complicated by idiopathic oligohydramnios. The end goal is to help physicians use the best drug for their patients.",[99],"Oligohydramnios","2025-08-13",{"date":102,"type":103},"2025-08-21","ACTUAL",{"date":105,"type":103},"2024-09-01",{"date":107,"type":93},"2025-12-31",{"name":5,"class":6},2]